Pi3k inhibitor wortmannin

According to the damage H/R model of endothelial cells, this experiment was divided into 8 groups: the control group, the H/R group (exposed to H/R), the miR-126 mimic group (miR-126 mimic+ H/R), the mimic-negative control (NC) group (mimic-NC + H/R), the miR-126 inhibitor group (miR-126 inhibitor + H/R), the inhibitor-NC group (inhibitor-NC + H/R), wortmannin group (PI3K inhibitor + H/R) and the miR-126 mimic + wortmannin group (miR-126 mimic, PI3K inhibitor + H/R). The oligonucleotide sequences was shown in Table 1 and synthesized by the Shanghai GenePharma Co., Ltd. (Shanghai, China). The transfected mixtures were configured according to the instructions of the Lipofectamine 2000 (Invitrogen Inc., Carlsbad, California, USA) kit. The control and H/R groups were administered only culture medium without serum and double antibody. The wortmannin group and miR-126 mimic +wortmannin group both were administered50nmol/L of PI3K inhibitor wortmannin (Sigma-Aldrich Chemical Company, St Louis, Missouri, USA). The other groups were treated with liposome (Invitrogen Inc., Carlsbad, California, USA) encapsulated oligonucleotide medium (final concentration of 20µmol/L).